

ADVOS Publications

Triebelhorn J, et al. 2026. Serum concentrations and pharmacokinetics of linezolid in critically ill patients dialyzed by ADVanced Organ Support compared to conventional continuous renal replacement therapy. *Eur J Clin Pharmacol*. 2026 Jul 10;82(8):199. doi: 10.1007/s00228-026-04129-0.



Himmelein S, et al. 2026. Effizienz der Harnsäure-Elimination mittels ADVOS im in vitro Tumorlysesyndrom-Modell. Abstracts der 57. Gemeinsamen Jahrestagung der ÖGIÄIN und DGIÄIN. *Med Klin Intensivmed Notfmed* 121, 417–444 (2026). <https://doi.org/10.1007/s00063-026-01447-0>.

Fuhrmann V, et al. 2025. The ADVanced Organ Support (ADVOS) hemodialysis system fulfills its intended purpose: Analysis of data from 282 patients from the Registry on Extracorporeal Multiple Organ Support (EMOS). *PLoS One*. 2025 Dec 4;20(12):e0318917. doi: 10.1371/journal.pone.0318917. eCollection 2025.



Dibos M, et al. 2025. The ADVanced Organ Support (ADVOS) hemodialysis system balances blood pH within 24 h in patients with multiple organ failure and hypercapnic acidosis. *Intensive Care Med Exp*. 2025 Oct 25;13(1):108. doi: 10.1186/s40635-025-00820-1

Panholzer B, et al. 2025. Accelerated Apixaban Removal by Using the ADVanced Organ Support (ADVOS) Albumin Hemodialysis System-A Case Report. *Thorac Cardiovasc Surg Rep*. 2025 Sep 15;14(1):e24-e28. doi: 10.1055/a-2682-8640



Schönfelder K, et al. 2025. Artificial liver support with Cytosorb and continuous veno-venous hemodiafiltration versus advanced organ support (ADVOS) for critically ill patients with hyperbilirubinemia and acute-on-chronic liver failure (ACLF). *BMC Nephrol*. 2025 Aug 4;26(1):432. doi: 10.1186/s12882-025-04342-6

Walter V, et al. 2025. The ADVanced Organ Support (ADVOS) Hemodialysis System in Postoperative Cardiogenic Shock and Multiple Organ Failure: First Results in Cardiac Surgery Patients. *Life* 2025, 15(7), 1042; <https://doi.org/10.3390/life15071042>



Totschnig D, et al. 2025. Meropenem plasma concentrations in critically ill patients treated with the novel multi organ replacement therapy ADVOS. *Infection* (2025). <https://doi.org/10.1007/s15010-025-02554-4>

Himmelein S, et al. 2025. The advanced organ support (ADVOS) hemodialysis system can remove myoglobin from blood: a proof-of-concept in vitro study. *Critical Care* 2025, 29(S1):P062



Triebelhorn J, et al. 2025. Comparison of linezolid elimination in albumin-based ADVOS dialysis versus conventional CVHD in critically ill patients. *Critical Care* 2025, 29(S1):P278

König C, et al. 2024. In vitro elimination of antimicrobials during ADVanced Organ Support hemodialysis. *Front. Pharmacol*. 15:1447511. doi: 10.3389/fphar.2024.1447511



Himmelein S, et al. 2024. The ADVanced Organ Support (ADVOS) hemodialysis system removes IL-6: an in vitro proof-of-concept study. *Intensive Care Med Exp*. 2024 Jul 31;12(1):66 doi: 10.1186/s40635-024-00652-5

Lahmer T, et al. 2024. The advanced organ support (ADVOS) hemodialysis system balances blood pH within 24 h in patients with multiple organ failure and hypercapnic acidosis. *Critical Care* 2024, 28(S1): P160



ADVOS Publications



Jahn M, et al. 2023: Extracorporeal liver support in acute-on-chronic liver failure grade 3 – ADVanced Organ Support versus plasma exchange. *Intensive Care Medicine Experimental* 2023, 11(Suppl 1)

Weinmann-Menke J, et al. 2024. Advanced organ support (ADVOS) in patients with acute-on-chronic liver failure: subgroup analysis of the Registry on Extracorporeal Multiple Organ Support. *Intensive Care Medicine Experimental* 2023, 11(Suppl 1):72



Sommerfeld O, et al. 2023. Extracorporeal albumin dialysis in critically ill patients with liver failure: Comparison of four different devices—A retrospective analysis. *Int J Artif Organs*. 2023 Sep;46(8-9):481-491. doi: 10.1177/03913988231191952.

Fuhrmann V, et al. 2023. Significant reduction of the standardized mortality ratio in patients with multiple organ failure treated with the Advanced organ support (ADVOS): analysis of the Registry on Extracorporeal Multiple Organ Support for patients with documented SOFA scores. *Critical Care* 2023, 27(S1): P310



Acharya MP, et al. 2022. The role of the ADVanced Organ Support (ADVOS) system in critically ill patients with multiple organ failure. *Artif Organs*. 2022 Feb 06. doi: 10.1111/aor.14188

Kaps L, et al. 2022. Influence of Advanced Organ Support (ADVOS) on Cytokine Levels in Patients with Acute-on-Chronic Liver Failure (ACLF). *J. Clin. Med.* 2022, 11(10), 2782; doi: 10.3390/jcm11102782



Frey O, et al. 2022. Antibiotika-Clearance mit dem ADVanced Organ Support (ADVOS) Hämodialysesystem. *DIVI 2022 – Abstractbuch - EP/ 12 /03*

Perez A, et al. 2022. Effektive Entfernung von IL-6 mit dem ADVanced Organ Support (ADVOS)-Verfahren: Proof-of-Concept in vitro. *DIVI 2022 – Abstractbuch - EP/ 12 /02*



Fuhrmann V, et al. 2022. Advanced organ support (ADVOS) in patients with acidosis and multiple organ failure: subgroup analysis of the registry on extracorporeal multiple organ support. *Critical Care* 2022, 26(Suppl 1): P143

Fuhrmann V, et al. 2021. Registry on extracorporeal multiple organ support with the advanced organ support (ADVOS) system: 2-year interim analysis. *Medicine (Baltimore)*. 2021 Feb 19;100(7):e24653



Allescher J, et al. 2021. Extracorporeal carbon dioxide Removal (ECCO2R) with the Advanced Organ Support (ADVOS) system in critically ill COVID-19 patients. *Artif Organs*. 2021 Jul 26. doi: 10.1111/aor.14044

Fuhrmann V, et al. 2020. Advanced organ support (ADVOS) in the critically ill: first clinical experience in patients with multiple organ failure. *Annals of Intensive Care* volume 10, Article number: 96 (2020)

